The in vitro effect of SB-497115 (Eltrombopag) on megakaryopoiesis of patients with low/intermediate-1 IPSS myelodysplastic syndrome

被引：0
|
作者：
Papadaki, H. [1 ]
Mavroudi, I. [1 ]
Psyllaki, M. [1 ]
Pyrovolaki, K. [1 ]
Papadaki, V. [1 ]
Kalpadakis, C. [1 ]
Mastrodimou, S. [1 ]
Kaparou, M. [1 ]
Kanellou, P. [1 ]
Gvazava, G. [1 ]
机构：
[1] Univ Crete, Sch Med, Dept Haematol, Iraklion, Greece
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70065-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S47 / S48
页数：2
相关论文
共 50 条
  • [1] STUDY OF THE IN VITRO EFFECT OF THE NONPEPTIDE THROMBOPOIETIN -RECEPTOR AGONIST SB-497115 (ELTROMBOPAG) ON MEGAKARYOPOIESIS OF PATIENTS WITH LOW/INTERMEDIATE-I RISK MYELODYSPLASTIC SYNDROME
    Mavroudi, I.
    Psyllaki, M.
    Pyrovolaki, K.
    Gvazava, G.
    Kalpadakis, C.
    Papadaki, H. A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 91 - 92
  • [2] OUTCOMES OF CONTINUED AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME IN IPSS LOW AND INTERMEDIATE-1
    Moon, J. H.
    Sohn, S. K.
    Cho, Y. Y.
    Kim, Y. K.
    Kim, H. J.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. K.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Yeon, J. Deok
    [J]. HAEMATOLOGICA, 2012, 97 : 141 - 141
  • [3] ELTROMBOPAG FOR THE TREATMENT OF THROMBOCYTOPENIA OF LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A PROSPECTIVE, RANDOMIZED, TRIAL
    Oliva, E.
    Santini, V.
    Zini, G.
    Palumbo, G.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M.
    Molteni, A.
    Sanpaolo, G.
    Liberati, A.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M.
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Raimondo, F.
    Leoni, P.
    Alimena, G.
    Fioritoni, G.
    Latagliata, R.
    Nobile, F.
    [J]. HAEMATOLOGICA, 2013, 98 : 456 - 456
  • [4] Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial
    Oliva, E. N.
    Santini, V.
    Zini, G.
    Palumbo, G. A.
    Poloni, A.
    Cortelezzi, A.
    Rodeghiero, F.
    Voso, M. T.
    Molteni, A.
    Sanpaolo, G.
    Liberati, M.
    Morabito, F.
    Balleari, E.
    Impera, S.
    Salvi, F.
    Spiriti, M. A. Aloe
    Marino, A.
    Roda, F.
    Alati, C.
    Ronco, F.
    Di Raimondo, F.
    Leoni, P.
    Alimena, G.
    Latagliata, R.
    Nobile, F.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S162 - S162
  • [5] Improved survival rates with continued treatment with hypomethylating agents in patients with myelodysplastic syndrome in IPSS low and intermediate-1
    Moon, J.
    Sohn, S. K.
    Kim, Y. K.
    Kim, H. J.
    Lim, S. N.
    Kim, M. K.
    Do, Y. R.
    Song, M. K.
    Lee, W. S.
    Lee, S. M.
    Kim, H.
    Won, J. H.
    Jo, D. Y.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S165 - S166
  • [6] Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome
    Marcel Merchan, Brayan
    Ortega, Margarita
    Jose Llamas-Poyato, Mara
    Cortes, Montserrat
    Arnan, Montserrat
    Cervero, Carlos
    Montoro, Julia
    Gimenez, Teresa
    Lopez, Mara
    Arenillas, Leonor
    Valcarcel, David
    [J]. BLOOD, 2014, 124 (21)
  • [7] ACQUISITION OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH IPSS LOW AND INTERMEDIATE-1 RISK. STUDY FROM THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROME
    Merchan, B.
    Ortega, M.
    Llamas-Poyato, M. J.
    Cortes, M.
    Arnan, M.
    Cervero, C.
    Montoro, J.
    Gimenez, T.
    Lopez, M.
    Arenillas, L.
    Valcarcel, D.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S136 - S136
  • [8] Unfavorable outcome of patients with myelodysplastic syndrome IPSS intermediate-1: Relationship to elevated expression of p53 at diagnosis
    Duarte, F.
    Filho, F.
    Barbosa, M.
    Santos, T.
    Goncalves, R.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S101 - S101
  • [9] PHASE 1 SAFETY OUTCOMES OF MESENCHYMAL STROMAL STEM CELL THERAPY IN PATEINTS WITH LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
    Cirillo, M.
    Carnley, B.
    Tan, P.
    Tan, D.
    Sturm, M.
    [J]. CYTOTHERAPY, 2018, 20 (05) : S31 - S31
  • [10] LONG TERM FOLLOW UP OF 5 PATIENTS TREATED WITH MESENCHYMAL STROMAL CELL IMMUNOMODULATORY THERAPY FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
    Tan, D.
    Carnley, B.
    Sturm, M.
    Cirillo, M.
    [J]. CYTOTHERAPY, 2024, 26 (06) : S40 - S40
12345